Supplementary Materials

Supplementary Materials for:

CHK1 as a therapeutic target to bypass chemoresistance in AML

Laure David, Anne Fernandez-Vidal, Sarah Bertoli, Srdana Grgurevic, Benoît Lepage, Dominique Deshaies, Naïs Prade, Maëlle Cartel, Clément Larrue, Jean-Emmanuel Sarry, Eric Delabesse, Christophe Cazaux, Christine Didier, Christian Récher,* Stéphane Manenti,* Jean-Sébastien Hoffmann*

*Corresponding author. Email: jean-sebastien.hoffmann{at}inserm.fr (J.-S.H.); stephane.manenti{at}inserm.fr (S.M.); recher.christian{at}iuct-oncopole.fr (C.R.)

This PDF file includes:

  • Fig. S1. Kaplan-Meier survivor functions according to BAALC, ERG, or MN1 expression.
  • Fig. S2. Analysis of relapse and death.
  • Fig. S3. Overall survival, relapse-free survival, and relapse incidence according to CHEK1 expression in allografted patients.
  • Fig. S4. Kaplan-Meier overall survivor functions according to CHEK1 expression in the favorable-risk group.
  • Table S1. Clinical characteristics of the cohort.
  • Table S2. Overall survival according to BAALC, ERG, or MN1 expression.
  • Legend for table S3
  • Table S4. Quantification method to determine CHK1 abundance in patient samples.

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 645 KB

Other Supplementary Material for this manuscript includes the following:

  • Table S3 (Microsoft Excel format). List of the genes tested for the analysis.

[Download Table S3]


Citation: L. David, A. Fernandez-Vidal, S. Bertoli, S. Grgurevic, B. Lepage, D. Deshaies, N. Prade, M. Cartel, C. Larrue, J.-E. Sarry, E. Delabesse, C. Cazaux, C. Didier, C. Récher, S. Manenti, J.-S. Hoffmann, CHK1 as a therapeutic target to bypass chemoresistance in AML. Sci. Signal. 9, ra90 (2016).

© 2016 American Association for the Advancement of Science